Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing.

Abstract

Seventy-five patients with pulmonary infection caused by Mycobacterium avium-intracellulare were studied to determine whether results of therapy correlated with in vitro susceptibility testing of mycobacterial isolates. Fifty patients responded to therapy and 25 were nonresponders. The total number of drugs received by responders did not differ significantly from the total number of drugs received by nonresponders. However, responders received significantly more drugs to which their isolate was susceptible in vitro than did nonresponders (2.4 +/- 1.2 versus 1.4 +/- 1.0, p less than 0.001). We conclude that patients with pulmonary M. avium-intracellulare infection should receive chemotherapeutic agents to which their isolate is susceptible in vitro.

• Authors: C R Horsburgh Jr, U G Mason 3rd, L B Heifets, K Southwick, J Labrecque, M D Iseman
• Journal: The American review of respiratory disease (Am Rev Respir Dis) Vol. 135 Issue 2 Pg. 418-21 (Feb 1987) ISSN: 0003-0805 [Print] United States
• PMID: 3813205 (Publication Type: Journal Article)

Chemical References

• Antitubercular Agents

Topics

• Antitubercular Agents (adverse effects, therapeutic use)
• Follow-Up Studies
• Humans
• Microbial Sensitivity Tests
• Mycobacterium avium
• Retrospective Studies
• Tuberculosis, Pulmonary (drug therapy)